Journal ArticleDOI
Antiseptic mouthwash for gonorrhoea prevention (OMEGA): a randomised, double-blind, parallel-group, multicentre trial
Eric P F Chow,Eric P F Chow,Deborah A Williamson,Jane S Hocking,Matthew Law,Kate Maddaford,Catriona S. Bradshaw,Anna McNulty,David J Templeton,David J Templeton,Richard D. Moore,Gerald L. Murray,Jennifer Danielewski,Rebecca Wigan,Marcus Y Chen,Rebecca Guy,Lei Zhang,Lei Zhang,Basil Donovan,Andrew E. Grulich,John M. Kaldor,David M. Whiley,Vincent J Cornelisse,Vincent J Cornelisse,Benjamin P Howden,David A. Lewis,Tim R H Read,Christopher K Fairley,Christopher K Fairley +28 more
Reads0
Chats0
TLDR
The OMEGA trial as mentioned in this paper compared the efficacy of Listerine and Biotene mouthwashes for preventing gonorrhoea among men who have sex with men (MSM).Abstract:
Summary Background To address the increasing incidence of gonorrhoea and antimicrobial resistance, we compared the efficacy of Listerine and Biotene mouthwashes for preventing gonorrhoea among men who have sex with men (MSM). Methods The OMEGA trial was a multicentre, parallel-group, double-blind randomised controlled trial among MSM, done at three urban sexual health clinics and one general practice clinic in Australia. Men were eligible if they were diagnosed with oropharyngeal gonorrhoea by nucleic acid amplification test (NAAT) in the previous 30 days or were aged 16–24 years. They were randomly assigned to receive Listerine (intervention) or Biotene (control) via a computer-generated sequence (1:1 ratio, block size of four). Participants, clinicians, data collectors, data analysts, and outcome adjudicators were masked to the interventions after assignment. Participants were instructed to rinse and gargle with 20 mL of mouthwash for 60 s at least once daily for 12 weeks. Oropharyngeal swabs were collected by research nurses every 6 weeks, and participants provided saliva samples every 3 weeks, to be tested for Neisseria gonorrhoeae with NAAT and quantitative PCR. The primary outcome was proportion of MSM diagnosed with oropharyngeal N gonorrhoeae infection at any point over the 12-week period, defined as a positive result for either oropharyngeal swabs or saliva samples by NAAT, and the cumulative incidence of oropharyngeal gonorrhoea at the week 12 visit. A modified intention-to-treat analysis for the primary outcome was done that included men who provided at least one follow-up specimen over the 12-week study period. The trial was registered on the Australian and New Zealand Clinical Trials Registry (ACTRN12616000247471). Findings Between March 30, 2016, and Oct 26, 2018, 786 MSM were screened and 256 were excluded. 264 MSM were randomly assigned to the Biotene group and 266 to the Listerine group. The analysis population included 227 (86%) men in the Biotene group and 219 (82%) in the Listerine group. Oropharyngeal gonorrhoea was detected in ten (4%) of 227 of MSM in the Biotene group and in 15 (7%) of 219 in the Listerine group (adjusted risk difference 2·5%, 95% CI −1·8 to 6·8). The cumulative incidence of oropharyngeal gonorrhoea at the week 12 visit did not differ between the two mouthwash groups (adjusted risk difference 3·1%, 95% CI −1·4 to 7·7). Interpretation Listerine did not reduce the incidence of oropharyngeal gonorrhoea compared with Biotene. However, previous research suggests that mouthwash might reduce the infectivity of oropharyngeal gonorrhoea; therefore, further studies of mouthwash examining its inhibitory effect on N gonorrhoeae are warranted to determine if it has a potential role for the prevention of transmission. Funding Australian National Health and Medical Research Council.read more
Citations
More filters
Journal ArticleDOI
Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial.
Christophe Van Dijck,Christophe Van Dijck,Achilleas Tsoumanis,Achilleas Tsoumanis,Anke Rotsaert,Bea Vuylsteke,Dorien Van den Bossche,Elke Paeleman,Irith De Baetselier,Isabel Brosius,Jolein Laumen,Jozefien Buyze,Kristien Wouters,Lutgarde Lynen,Marjan Van Esbroeck,Natacha Herssens,Saïd Abdellati,Steven Declercq,Thijs Reyniers,Yven Van Herrewege,Eric Florence,Chris Kenyon,Chris Kenyon +22 more
TL;DR: In this paper, the use of an antiseptic mouthwash as an antibiotic sparing approach to prevent STIs was evaluated in the AB/BA crossover superiority trial at the Institute of Tropical Medicine in Antwerp, Belgium.
Journal ArticleDOI
An open-label, parallel-group, randomised controlled trial of antiseptic mouthwash versus antibiotics for oropharyngeal gonorrhoea treatment (OMEGA2).
Eric P F Chow,Eric P F Chow,Kate Maddaford,Jane S Hocking,Catriona S. Bradshaw,Rebecca Wigan,Marcus Y Chen,Benjamin P Howden,Deborah A Williamson,Deborah A Williamson,Christopher K Fairley +10 more
TL;DR: A 14-day course of mouthwash failed to cure a high proportion of oropharyngeal gonorrhoea cases and was stopped early due to a high failure rate in the mouthwash arm.
Journal ArticleDOI
The SARS-CoV2 envelope differs from host cells, exposes procoagulant lipids, and is disrupted in vivo by oral rinses
Andreas Zaragkoulias,Evelina Statkute,Kirsten Bentley,Patricia Rodrigues,Robert G. Newcombe,James E. Heyman,Arvind Arya,Ceri Lynch,David Owens,P. Vince Jenkins,David Thomas,Richard J. Stanton,Zack Saud,Victoria J. Tyrrell,Majd B. Protty,Anzelika Rubina,Daniel A. White,Robert C. Murphy,Harald Köfeler,William J. Griffiths,Jorge Alvarez-Jarreta,Richard W. Brown,Manon F. Pritchard,Robert McLeod,Niklaas J. Buurma,Valerie B. O'Donnell +25 more
TL;DR: The lipid envelope of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an essential component of the virus; however, its molecular composition is undetermined as discussed by the authors .
Journal ArticleDOI
The SARS-CoV2 envelope differs from host cells, exposes procoagulant lipids, and is disrupted in vivo by oral rinses
Zack Saud,Victoria J. Tyrrell,Kirsten Bentley,Patricia Rodrigues,Robert C. Murphy,Harald Köfeler,William J. Griffiths,Jorge Alvarez-Jarreta,Richard W. Brown,Robert G. Newcombe,James E. Heyman,Robert McLeod,David Owens,P. Vince Jenkins,Niklaas J. Buurma,Valerie B. O'Donnell,Andreas Zaragkoulias,Majd B. Protty,Evelina Statkute,Anzelika Rubina,Daniel A. White,Manon F. Pritchard,Arvind Arya,Ceri Lynch,David Thomas,Richard J. Stanton +25 more
TL;DR: The lipid envelope of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an essential component of the virus; however, its molecular composition is undetermined as mentioned in this paper .
Journal ArticleDOI
Anti-Virulence Therapeutic Approaches for Neisseria gonorrhoeae.
Katherine Y. L. Lim,Christopher A. Mullally,Ethan C. Haese,Emily A Kibble,Emily A Kibble,Nicolie R. McCluskey,Nicolie R. McCluskey,Edward C. Mikucki,Van C. Thai,Keith A. Stubbs,Mitali Sarkar-Tyson,Charlene M. Kahler +11 more
TL;DR: A review highlighting the growing research interest in developing anti-virulence therapies (AVTs) which are directed towards inhibiting virulence factors to prevent infection is presented in this paper, where it is hypothesized that this will impart a smaller selective pressure for the emergence of resistance in the pathogen and in the microbiome, thus avoiding AMR development to the antiinfective.
References
More filters
Journal ArticleDOI
Sexually transmitted infections: challenges ahead
Magnus Unemo,Catriona S. Bradshaw,Jane S Hocking,Henry J. C. de Vries,Suzanna C. Francis,David Mabey,Jeanne M. Marrazzo,Gerard J.B. Sonder,Jane R. Schwebke,Elske Hoornenborg,Rosanna W. Peeling,Susan S. Philip,Nicola Low,Christopher K Fairley +13 more
TL;DR: Overall, this Commission aims to enhance the understanding of some of the key challenges facing the field of STI treatment and control, and outlines new approaches to improve the clinical management of STIs and public health.
Journal ArticleDOI
Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data.
TL;DR: This paper shows how model-adjusted risks, risk differences, and risk ratio estimates can be obtained directly from logistic regression models in the complex sample survey setting to yield population-based inferences.
Journal ArticleDOI
Computing Adjusted Risk Ratios and Risk Differences in Stata
TL;DR: In this article, a post-estimation command, adjrr, is proposed to calculate adjusted risk ratios and adjusted risk differences after running a logit or probit model with a binary, a multinomial, or an ordered outcome.
Journal ArticleDOI
World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts
Magnus Unemo,Monica M Lahra,Michelle J Cole,P Galarza,Francis Ndowa,Irene Martin,Jo-Anne R. Dillon,Pilar Ramon-Pardo,Gail Bolan,Teodora Wi +9 more
TL;DR: The World Health Organization GASP data from 67 countries in 2015-16 is described, confirmed gonorrhoea treatment failures with ceftriaxone with or without azithromycin or doxycycline, and international collaborative actions and research efforts essential for the effective management and control of gonor rhoea are described.
Journal ArticleDOI
Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17.
Martin Holt,Toby Lea,Toby Lea,Limin Mao,Johann Kolstee,Iryna Zablotska,Iryna Zablotska,Tim Duck,Brent Allan,Michael West,Evelyn Lee,Peter Hull,Andrew E. Grulich,John de Wit,Garrett Prestage +14 more
TL;DR: A rapid increase in PrEP use by gay and bisexual men in Melbourne and Sydney was accompanied by an equally rapid decrease in consistent condom use, and other jurisdictions should consider the potential for community-level increases in CAIC when modelling the introduction of PrEP and in monitoring its effect.
Related Papers (5)
Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial.
Christophe Van Dijck,Christophe Van Dijck,Achilleas Tsoumanis,Achilleas Tsoumanis,Anke Rotsaert,Bea Vuylsteke,Dorien Van den Bossche,Elke Paeleman,Irith De Baetselier,Isabel Brosius,Jolein Laumen,Jozefien Buyze,Kristien Wouters,Lutgarde Lynen,Marjan Van Esbroeck,Natacha Herssens,Saïd Abdellati,Steven Declercq,Thijs Reyniers,Yven Van Herrewege,Eric Florence,Chris Kenyon,Chris Kenyon +22 more
Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial
Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial
Holly Fisher,Yemi Oluboyede,Thomas Chadwick,Mohamed Abdel-Fattah,Catherine Brennand,Mandy Fader,Simon Harrison,Paul Hilton,James Larcombe,Paul Little,Doreen McClurg,Elaine McColl,James N'Dow,Laura Ternent,Nikesh Thiruchelvam,Anthony G. Timoney,Luke Vale,Katherine Walton,Alexander von Wilamowitz-Moellendorff,Jennifer Wilkinson,Ruth Wood,Robert Pickard +21 more